. . July 30, 2024 8:00 AM EDT | Source: InMed Pharmaceuticals Vancouver, British Columbia--(Newsfile Corp. - July 30, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced positive results from initial data sets from a long-term (7 months of dosing) in vivo preclinical Alzheimer's Disease ("AD") study of INM-901 which confi ...

. . ● . InMed to Present at the Emerging Growth Conference June 10, 2024 5:18 PM EDT | Source: InMed Pharmaceuticals Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, today announced the Company will be presenting at the upcoming Emerging Growth Conference scheduled for June 12-13, 2024. InMed's CEO, Mr. Eri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98- ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR For the transition period from to Commission file number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) | British Columbia, Canada | 98-1428279 | | --- | --- | | (State or other jurisdiction of | (IRS employer | | incorporation or organization ...

Financial Performance - For the nine months ended March 31, 2023, InMed Pharmaceuticals reported a net loss of $7.6 million, compared to a net loss of $10.7 million for the same period in 2022, indicating a reduction in losses of approximately 29%[100]. - InMed Pharmaceuticals reported a net loss of $1.6 million for the three months ended March 31, 2023, a decrease of 45% compared to a net loss of $2.9 million in the same period of 2022[125]. - For the nine months ended March 31, 2023, net cash used in operating activities was $6.6 million, a decrease from $11.5 million for the same period in 2022, reflecting a 42% improvement[149][150][151]. - InMed Pharmaceuticals expects to incur substantial operating losses and negative cash flows for the foreseeable future due to ongoing research and development activities[155]. - The accumulated deficit stood at $101.1 million, reflecting an increase of approximately $72.2 million since 2014 when the company began focusing on cannabinoid-derived pharmaceuticals[100]. Research and Development - Research and development expenses decreased in fiscal 2023 compared to fiscal 2022, primarily due to high start-up costs associated with the multicenter Phase II clinical trial in the INM-755 program during fiscal 2022[116]. - The company expects significant increases in research and development expenses in future periods as it advances drug candidates and manufacturing technologies through clinical development[116]. - Research and development expenses in the InMed segment decreased by $0.7 million, or 49%, for the three months ended March 31, 2023, primarily due to lower personnel expenses and decreased costs related to the INM-755 program[126]. - Research and development expenses in the BayMedica segment decreased by $0.2 million, or 21%, for the nine months ended March 31, 2023, primarily due to lower personnel expenses[144]. Sales and Revenue - Sales in the BayMedica segment increased by $1.0 million, or 234%, for the three months ended March 31, 2023, compared to the same period in 2022, driven by expanded marketing efforts and increased demand[129]. - For the nine months ended March 31, 2023, sales in the BayMedica segment increased by $1.2 million, or 217%, compared to the same period in 2022[140]. - The cost of goods sold in the BayMedica segment increased by $1.1 million, or 404%, for the nine months ended March 31, 2023, reflecting the increase in sales[141]. Operating Expenses - Total operating expenses for the InMed segment decreased by 43% to $1.7 million for the three months ended March 31, 2023, down from $3.0 million in the same period of 2022[125]. - General and administrative expenses in the InMed segment decreased by $0.6 million, or 38%, for the three months ended March 31, 2023, attributed to lower investor relation expenses and stock-based compensation[127]. - General and administrative expenses in the BayMedica segment increased by $0.7 million, or 107%, for the nine months ended March 31, 2023, due to the inclusion of BayMedica's operating results post-acquisition[146]. Funding and Financial Position - InMed Pharmaceuticals has funded its operations primarily through the issuance of common shares since the acquisition of Biogen Sciences Inc. in 2014[99]. - The company plans to finance its operations through product sales, equity sales, debt financing, and collaborations, but may face challenges in raising additional funds[103]. - Cash provided by financing activities for the nine months ended March 31, 2023, was $10.7 million, slightly up from $10.0 million in the same period in 2022[153][154]. - The company anticipates that its current cash and cash equivalents will be sufficient to fund operations into the first quarter of calendar 2024, depending on revenue realization from BayMedica[158][172]. - InMed Pharmaceuticals has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the issuance of the financial statements[159][173]. - The company plans to seek additional funding through equity or debt financings and collaborations, but there are uncertainties regarding the ability to obtain financing on acceptable terms[160][174]. Legal and Compliance - A licensor has alleged a breach of an agreement during the three months ended March 31, 2023, which may impact the company's operations[105]. - The company is implementing a remediation plan to address a previously reported material weakness in internal control over financial reporting, expected to be completed before the end of fiscal year 2023[179]. - The financial statements are believed to fairly present the company's financial position, results of operations, and cash flows in conformity with U.S. GAAP despite the material weakness[179]. - The company is not currently involved in any active legal proceedings that are considered material[181]. - As a smaller reporting company, the company is electing scaled disclosure reporting obligations and is not required to provide certain risk factor information[182].

| --- | --- | --- | --- | --- | --- | --- | --- | |--------------|-------|------------------------|-------|-------|-------|-------|---------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation | | | | | | | MARCH 2023 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | www.inmedpharma.com | Forward Looking Statements With re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1428279 (State or other jurisdiction of incorporation or organization) Suite 310 - 815 W. Hastings Street, Vancouver, B.C. (Address of Principal Executive Offices) (Zip Code) (604) 669-7207 ☐ TRANSITION RE ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...